Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
Key Highlights
- ➤November 3 investor event will detail Phase 3 ARCHER II trial design
- ➤15-month and 24-month ARCHER II results anticipated beginning in Q4 2026
- ➤Annexon will discuss strengthened Ophthalmology team at virtual event
- ➤Roger Goldberg, MD, MBA will join management as ARCHER II clinical investigator
Expert Statements
Roger A. Goldberg, MD, MBA; Bay Area Retina Associates and ARCHER II Clinical Investigator
“The event will feature Roger Goldberg, MD, MBA (Bay Area Retina Associates and ARCHER II Clinical Investigator), who will join company management to discuss the unmet need and current treatment landscape for geographic atrophy (GA), the advanced form of dry, age-related macular degeneration (AMD) of the retina.”
BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host a virtual investor event on Tuesday, November 3, 2026 at 11:00 AM ET regarding the ARCHER II Phase 3 program. To register, click here.
Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will also highlight the recent strengthening of its Ophthalmology team.
Get started
Create a free account to read the full story.